

Copyright is owned by the Author of the thesis. Permission is given for a copy to be downloaded by an individual for the purpose of research and private study only. The thesis may not be reproduced elsewhere without the permission of the Author.

**INVESTIGATIONS OF A NOVEL
LYMPHOPROLIFERATIVE DISEASE
IN
BRITISH SHORTHAIK KITTENS**

A thesis presented in partial fulfilment
of the requirements for the degree
of Doctor of Philosophy

at

Massey University,
Palmerston North,
New Zealand

Danielle Aberdein

2013

ABSTRACT

In 2009, three sibling British shorthair (BSH) kittens presented with lymphoproliferative disease (LPD) causing massive enlargement of multiple lymph nodes, a presentation that suggested an inherited predisposition to the disease. While aspects of the disease presentation suggested a diagnosis of lymphoma, other features were inconsistent with lymphoid neoplasia. In particular, the consistently young age of affected kittens, the pattern of disease affecting multiple littermates, and the presence of such marked generalised lymphadenopathy, were all atypical for feline lymphoma. This unusual constellation of clinical and pathologic features in affected BSH kittens had not been previously reported in cats but had several similarities to the human disease autoimmune lymphoproliferative syndrome (ALPS), a rare inherited disorder causing persistent LPD, increased numbers of CD3+/CD4-/CD8- double negative T-cells (DNT cells) and variable manifestations of autoimmunity. The majority of human ALPS patients have inherited *Fas* gene mutations causing defective T-cell apoptosis, although in some patients the cause of disease is still unknown.

The thesis further describes and investigates this novel LPD in BSH kittens. The results of breeding trials, pedigree information and reviews of historical records support an inherited basis for the disease, most likely with either a simple autosomal recessive or modified autosomal dominant mode of inheritance. The typical clinical presentation is the development of a massive multicentric lymphadenopathy, splenomegaly and probable haemolytic anaemia in previously healthy kittens between 5 to 7 weeks of age. Microscopic pathology and immunophenotypic studies are suggestive of multicentric T-cell lymphoma affecting the lymph nodes, spleen, and sometimes other organs, but clonality assays confirm a non-clonal and likely non-neoplastic T-cell LPD. Where tested, the proliferating T-cells show a DNT cell immunophenotype and reduced apoptosis on *in situ* methods. Qualitative *Fas* gene abnormalities were not identified in affected kittens using reverse-transcriptase polymerase chain reaction techniques.

The studies described in the thesis therefore confirm a novel and likely non-neoplastic T-cell LPD in BSH kittens with a probable inherited basis. Results support defective T-cell

apoptosis as a possible factor in disease development, although causative genetic abnormalities have not yet been identified. The disease in kittens has several similarities to ALPS in people, although the apparent absence of *Fas* gene abnormalities in affected kittens may limit the use of the feline disease as a disease model for ALPS.

ACKNOWLEDGMENTS

At times this project has felt like a Sisyphean task, and getting the rock to the top of the hill would not have been possible without the help of an enormous number of people. I have been extremely fortunate to have such a fantastic supervisory team. John Munday has guided the project from start to finish, provided excellent support, advice and humour throughout, and rescued me from the depths of despondency on many occasions (sarcastic red pen notwithstanding). Keith Thompson and Fran Wolber have also provided invaluable advice, encouragement and practical assistance, and I am extremely grateful for their input. The generous financial support provided by the Vice-Chancellor's Doctoral Scholarship, the Palmerston North Medical Research Fund and the Institute of Veterinary, Animal and Biomedical Sciences Postgraduate Fund has funded many aspects of the research, and has been essential to its completion.

Huge thanks must also go to Rob Fairley at Gribbles Veterinary Pathology for his initial identification of the disease and assistance in uncovering further cases. Thanks also to Rae Pearson and her staff at New Zealand Veterinary Pathology for help processing samples and arranging their overseas transport, as well as allowing me free rein of their laboratory. The help and advice of Bill Vernau, Leslie Lyons and Niels Pedersen at UC Davis, particularly with regard to the immunophenotyping and clonality studies, has been immensely important to the thesis and very much appreciated. I am grateful to George Davis and Clive Felix at Capital & Coast District Health Board for allowing me to spend time in their genetics laboratory and taking the time taken to teach me cell culture and karyotyping techniques. Numerous people have assisted with housing, feeding, cleaning, socialising and drawing blood from small, uncooperative and often rather sharp-clawed kittens and cats, and I thank Dave Thomas and his staff at the Centre for Feline Nutrition, Debbie Chesterfield and Margaret Brown at the Small Animal Production Unit, and Emma Bermingham and Mike Kelly, who allowed their home to be turned into a kitten farm on two occasions. The contributions of several cat breeders to the project have been vital, particularly those of Iris Baker and Daniel Wheeler, whose immense generosity in loaning Luci (Q1) and progeny to me for the duration of the project I still find slightly unbelievable. Thanks also to the many British shorthair breeders who contributed advice

and information but who do not wish to be acknowledged by name, and who at times must have felt that assisting me with this project ran counter to their own interests.

The support of my pathology colleagues throughout the project has been incredible, and I could not have completed the thesis without their help. I am forever in debt to Keren Dittmer, unofficial supervisor, unstinting provider of advice both technical and practical, rocker of the free world, and perpetually optimistic officemate and friend. Thanks must also go to Eloise Jillings, Mark Collett, Hayley Dann and Keren (again), for relieving me of various teaching commitments to allow me to complete the project. I also thank Laryssa Howe, Matthew Perrott, Evelyn Lupton and Mike Hogan for help with molecular techniques, immunohistochemistry, sample processing and equipment sourcing in general, and to Wendi Roe and Stu Hunter for keeping me somewhat sane throughout the process.

Finally, and at the risk of sounding like a bad Academy award acceptance speech, I would like to thank my family, most of whom thought I was insane for embarking on this madness but have supported me nonetheless. I promise this is the last time. Probably. Particular thanks to my parents, Keith and Joy, for their endless encouragement, support, and (I suspect, often feigned) interest in the lymphoproliferative diseases of the cat and the conundrum of the double negative T-cell. Last, but definitely not least, thank you to Thomas, my ginger kiss, and to Bella, the best dog in the world. Your patience and love is unrivalled. And yes, Thomas, I think your mum has finally finished her "P Haitch D".

TABLE OF CONTENTS

List of Figures.....	xiii
List of Tables.....	xv
Abbreviations	xvii
1. Prologue	1
1.1 Introduction and problem statement	1
1.2 Research aim	3
1.3 Overview of thesis structure	3
1.4 Terminology	4
1.5 References.....	4
2. Background and review of the literature	7
2.1 Introduction.....	7
2.2 Lymphocyte development.....	8
2.3 Neoplastic lymphoproliferative diseases	12
2.3.1 General principles of lymphoma diagnosis	12
2.3.1.1 Microscopic pathology.....	12
2.3.1.2 Immunophenotype	14
2.3.1.3 Clonality	16
2.3.2 Lymphoma in people	18
2.3.2.1 Classification systems	18
2.3.2.2 Familial lymphoma.....	19
Genomic instability syndromes.....	19
Immune deficiency syndromes	21
Autoimmune diseases.....	22
Shared environmental exposures	23
2.3.3 Lymphoma in cats	25
2.3.3.1 Sporadic lymphoma	26
2.3.3.2 Familial lymphoma.....	29
2.3.3.3 Feline leukaemia virus-associated lymphoma	30
2.3.3.4 Feline immunodeficiency virus-associated lymphoma.....	33
2.4 Non-neoplastic lymphoproliferative diseases.....	36
2.4.1 Diseases in people.....	36

2.4.1.1	Viral infections	36
2.4.1.2	Castleman's disease	37
2.4.1.3	Kikuchi-Fujimoto disease	38
2.4.1.4	Progressive transformation of germinal centres	39
2.4.1.5	Common variable immunodeficiency	39
2.4.1.6	Autoimmune diseases	40
2.4.2	Diseases in cats	41
2.4.2.1	Feline immunodeficiency virus-associated lymphadenopathy....	41
2.4.2.2	Distinctive peripheral lymph node hyperplasia of young cats....	42
2.4.2.3	Generalised lymphadenopathy resembling lymphoma.....	43
2.4.2.4	Plexiform vascularisation of lymph nodes	44
2.5	Autoimmune lymphoproliferative syndrome	44
2.5.1	Molecular and genetic basis for disease	45
2.5.1.1	Lymphocyte apoptosis	45
2.5.1.2	Defects in Fas-mediated apoptosis.....	46
2.5.1.3	Double negative T-cells.....	48
2.5.1.4	Penetrance of the genotype	49
2.5.2	Clinical features.....	50
2.5.2.1	Lymphoproliferation	50
2.5.2.2	Autoimmunity	50
2.5.2.3	Lymphoma development.....	51
2.5.3	Laboratory findings	51
2.5.4	Pathologic features	53
2.5.5	Diagnosis	54
2.5.6	Treatment and prognosis.....	56
2.5.7	Animal models – <i>lpr</i> and <i>gld</i> disease	57
2.6	References.....	59
3. Disease inheritance		77
3.1	Introduction.....	77
3.2	Materials and methods	79
3.2.1	Breeding trials	79
3.2.1.1	Repeat of initial mating – Litter 2	80
3.2.1.2	Outcross mating – Litter 3.....	80
3.2.1.3	Sibling matings – Litters 4, 5 and 7	80
3.2.1.3	Backcross mating – Litter 6	81
3.2.1.5	Data and sample collection.....	81
3.2.2	Identification of further historical cases	81
3.2.3	Pedigree reconstructions	82
3.2.4	Data analysis	82
3.2.4.1	Goodness of fit tests	82
3.2.4.2	Inbreeding co-efficient.....	83

3.3	Results	83
3.3.1	Breeding trials	83
3.3.1.1	Repeat of initial mating – Litter 2	83
3.3.1.2	Outcross mating – Litter 3.....	84
3.3.1.3	Sibling matings – Litters 4, 5 and 7	84
3.3.1.4	Backcross mating – Litter 6.....	85
3.3.2	Identification of further historical cases.....	85
3.3.3	Pedigree reconstructions	86
3.3.4	Data analysis	86
3.4	Discussion.....	92
3.5	Summary	100
3.6	References.....	101

4. Clinical presentation and pathology..... 105

4.1	Introduction.....	105
4.2	Materials and methods	106
4.2.1	Animals used	106
4.2.2	Clinical features.....	106
4.2.3	Haematology and biochemistry.....	107
4.2.4	FeLV and FIV testing.....	109
4.2.5	Pathology	109
4.2.5.1	Cytology	109
4.2.5.2	Gross pathology	109
4.2.5.3	Histology	109
4.2.6	Data analysis	110
4.3	Results	110
4.3.1	Animals used	110
4.3.2	Clinical features.....	111
4.3.3	Haematology and biochemistry.....	113
4.3.4	FeLV and FIV testing.....	116
4.3.5	Pathology	116
4.3.5.1	Cytology	116
4.3.5.2	Gross pathology	118
4.3.5.3	Histology	121
4.4	Discussion.....	127
4.5	Summary	138
4.6	References.....	138

5. Further characterisations of disease 143

5.1	Introduction.....	143
5.2	Materials and methods	144
5.2.1	Investigations of chromosomal abnormalities	144

5.2.2	Investigations of lymphoid cellular phenotype.....	146
5.2.2.1	Immunohistochemistry.....	146
5.2.2.2	Immunocytochemistry.....	148
5.2.2.3	Flow cytometry.....	149
5.2.3	Clonality studies.....	151
5.3	Results.....	154
5.3.1	Investigations of chromosomal abnormalities.....	154
5.3.2	Investigations of lymphoid cellular phenotype.....	155
5.3.2.1	Immunohistochemistry.....	155
5.3.2.2	Immunocytochemistry.....	159
5.3.2.3	Flow cytometry.....	160
5.3.3	Clonality studies.....	162
5.4	Discussion.....	164
5.5	Summary.....	173
5.6	References.....	173
6.	Investigations of defective lymphocyte apoptosis	177
6.1	Introduction.....	177
6.2	Materials and methods.....	178
6.2.1	Lymphocyte apoptosis <i>in situ</i>	178
6.2.2	Lymphocyte apoptosis <i>in vitro</i>	181
6.2.3	Qualitative <i>Fas</i> -gene abnormalities.....	183
6.3	Results.....	185
6.3.1	Lymphocyte apoptosis <i>in situ</i>	185
6.3.2	Lymphocyte apoptosis <i>in vitro</i>	188
6.3.3	Qualitative <i>Fas</i> -gene abnormalities.....	188
6.4	Discussion.....	191
6.5	Summary.....	200
6.6	References.....	201
7.	Investigations of defective mismatch repair	205
7.1	Introduction.....	205
7.2	Materials and methods.....	207
7.2.1	Validation of human MMR antibodies in feline tissue.....	207
7.2.2	Immunohistochemical analysis of MMR expression.....	208
7.3	Results.....	209
7.3.1	Validation of human MMR antibodies in feline tissue.....	210
7.3.2	Immunohistochemical analysis of MMR expression.....	212
7.4	Discussion.....	217
7.5	Summary.....	220
7.6	References.....	221
	Statement of contribution.....	225

8. General discussion and conclusions	227
8.1 Introduction.....	227
8.2 Features of lymphoproliferative disease in British shorthair kittens.....	228
8.3 Basis for disease development.....	230
8.4 Similarities to reported lymphoproliferative diseases.....	232
8.5 Study limitations.....	234
8.6 Conclusions and future directions.....	237
8.7 References.....	238

Appendix: Pre- and post mortem sampling protocol for kittens affected by lymphoproliferative disease	241
---	------------

LIST OF FIGURES

Figure 2.1	Lymphocyte development and expression of selected CD markers	11
Figure 2.2	Schematic diagram of lymph node showing normal architecture appreciable histologically	14
Figure 2.3	Diagram of human <i>Fas</i> gene showing the location and nature of mutations known to cause ALPS-FAS	48
Figure 3.1	Extended pedigree of LPD-affected kittens and cats	87
Figure 4.1	Litter 2 kittens at 6 weeks of age, LPD-affected and unaffected	112
Figure 4.2	Weekly bodyweight measurements for Litter 2, birth to 12 weeks.....	113
Figure 4.3	Packed cell volume % (PCV) differences between LPD-affected and unaffected kittens	115
Figure 4.4	Lymph node cytology, LPD-affected kittens (K10 and K32), Diff-Quik....	117
Figure 4.5	Gross pathology - multicentric lymphadenopathy, LPD-affected kittens (K2 and K10).....	119
Figure 4.6	Gross pathology - viscera, LPD-affected adult cat (K11)	120
Figure 4.7	Lymph node histology (low power), LPD-affected and control animals, haematoxylin and eosin	122
Figure 4.8	Lymph node histology (high power), LPD-affected kittens, haematoxylin and eosin	123
Figure 4.9	Splenic histology (low, medium and high power), LPD-affected kittens and control kitten, haematoxylin and eosin.....	124
Figure 4.10	Hepatic histology (low, medium and high power), LPD-affected animals, haematoxylin and eosin	126
Figure 5.1	Karyotype of LPD-affected kitten (K10).....	155
Figure 5.2	Lymph node immunohistochemistry, CD3 and CD79a (low power), LPD-affected kittens and cats, 3,3'diaminobenzidine/haematoxylin.....	157
Figure 5.3	Splenic and hepatic immunohistochemistry, CD3 and CD79a (low and medium power), LPD-affected kittens, 3,3'diaminobenzidine/haematoxylin	159
Figure 5.4	Representative (Q1) histogram and dot plots of flow cytometry analysis	161

Figure 5.5	<i>TCRG</i> clonality results for lymph node samples using capillary electrophoresis	163
Figure 5.6	Typical <i>TCRG</i> clonality results from monoclonal, polyclonal and pseudoclonal samples using capillary electrophoresis	163
Figure 6.1	TUNEL assay (high power), showing apoptosis in control lymph nodes, LPD-affected kittens and sporadic lymphoma, 3,3'diaminobenzidine/haematoxylin	187
Figure 6.2	TUNEL assay (low and high power), showing apoptosis in germinal centre remnant of LPD-affected kitten (K32), 3,3'diaminobenzidine/haematoxylin	188
Figure 6.3	Reverse transcription-polymerase chain reaction (RT-PCR) analyses for the coding region of feline <i>Fas</i> in LPD-affected and control animals.....	190
Figure 7.1	Western blot analysis showing cross-reactivity of human mismatch repair (MMR) antibodies with feline tissue	211
Figure 7.2	Lymph node immunohistochemistry, MLH1, MSH2, and MSH6 (low and high power), LPD-affected kitten (K2), 3,3'diaminobenzidine/haematoxylin	213
Figure 7.3	Small intestinal immunohistochemistry, MLH1, MSH2, and MSH6 (low power), low and high grade tumours, 3,3'diaminobenzidine/haematoxylin	216

LIST OF TABLES

Table 2.1	Selected CD antibodies previously used in the identification of feline lymphocyte subpopulations by various immunophenotyping techniques (immunohistochemistry, immunocytochemistry and flow cytometry)	16
Table 2.2	Current diagnostic criteria for ALPS in people	55
Table 3.1	Kittens and cats included in mode of inheritance studies	89
Table 3.2	Inbreeding co-efficients (F) for Litters 0-7 based on available pedigree information.....	92
Table 4.1	Sample availability for LPD-affected kittens and cats	110
Table 4.2	Relevant haematology and biochemistry results from LPD-affected kittens and cats	114
Table 5.1	List of primers used in polymerase chain reactions (PCR) to assess <i>TCRG</i> and <i>IGH</i> rearrangements for clonality determination	153
Table 5.2	Mean percentages and ranges of peripheral CD5+, CD21+ and DNT cells in control cats, siblings and parents of LPD-affected kittens, and unaffected litters by flow cytometry	162
Table 6.1	List of primer pairs used in reverse transcription-polymerase chain reactions (RT-PCR) and sequencing of feline <i>Fas</i>	185
Table 6.2	Mean apoptotic index (AI) and apoptotic rate (AR) of lymph nodes of LPD-affected kittens and cats, normal control cats, and unrelated cats with sporadic lymphoma by TUNEL assay.	186
Table 7.1	Summary of mismatch protein repair (MMR) expression within feline small intestinal lymphomas.....	214
Table A.1	Recommended pre-mortem samples to be taken from LPD-affected kittens and cats	242
Table A.2	Recommended post-mortem samples to be taken from LPD-affected kittens and cats	245

ABBREVIATIONS

AAFCO	American Association of Feed Control Officials
AI	apoptotic index, a measure of the level of apoptosis present within the relevant tissue field(s) using the number of apoptotic cells as the basis for calculation
ALL	acute lymphoblastic leukaemia
ALPS	autoimmune lymphoproliferative syndrome, a human disease of defective lymphocyte apoptosis resulting in lymphoproliferation including lymphadenopathy and splenomegaly and variable manifestations of autoimmunity
ALPS-CASP10	People fulfilling the diagnostic criteria for autoimmune lymphoproliferative syndrome (ALPS) with either germline or somatic mutations in the caspase 10 (<i>CASP10</i>) gene
ALPS-FAS	People fulfilling the diagnostic criteria for autoimmune lymphoproliferative syndrome (ALPS) with either heterozygous or homozygous germline mutations in the <i>Fas</i> gene
ALPS-FASLG	People fulfilling the diagnostic criteria for autoimmune lymphoproliferative syndrome (ALPS) with germline mutations in the <i>Fas ligand</i> gene
ALPS related disease	Diseases in people with similar clinical signs and pathology to autoimmune lymphoproliferative syndrome (ALPS) but not meeting the diagnostic criteria for ALPS. ALPS-related disorders include caspase-8 deficiency state, RAS-associated autoimmune leukoproliferative disease, Dianzani autoimmune lymphoproliferative syndrome and X-linked lymphoproliferative syndrome.
ALPS-sFAS	People fulfilling the diagnostic criteria for autoimmune lymphoproliferative syndrome (ALPS) with somatic mutations in the <i>Fas</i> gene
ALPS-U	People fulfilling the diagnostic criteria for autoimmune lymphoproliferative syndrome (ALPS) without a determined genetic defect
ANOVA	analysis of variance
AR	apoptotic rate, a measure of the level of apoptosis present within the relevant tissue field(s) using apoptotic area as the basis for calculation
AT	ataxia-telangiectasia
<i>ATM</i>	the ataxia telangiectasia mutated gene
BSH	British shorthair breed of cat
<i>CASP10</i>	the caspase 10 gene
CBC	complete blood count

CD	cluster of differentiation
CD3	cluster of differentiation antigen 3, a protein complex associated with the T-cell receptor (TCR) complex on mature T-cells and composed of 4 distinct chains (γ , δ and two ϵ chains)
CD4	cluster of differentiation antigen 4, a glycoprotein predominantly expressed by and on the surface of helper T-cells
CD8	cluster of differentiation antigen 4, a transmembrane glycoprotein predominantly expressed by and on the surface of cytotoxic T-cells usually composed of α and β chains
CMA	chromosomal microarray analysis
Coombs test	blood test used to detect the presence of antibodies to erythrocytes and providing evidence of immune-mediated erythrocyte destruction and immune-mediated haemolytic anaemia
ConA	<i>Concanavalia ensiformis</i> type IV-S
CRT	capillary refill time
CTLA-4	cytotoxic T-lymphocyte antigen 4
CVID	combined variable immunodeficiency
Cy5	cyanine 5, a fluorescent dye used in flow cytometry
DAB	3,3-diaminobenzidine, a chromagen used in immunohistochemistry
DMEM	Dulbecco's Modified Eagle Medium
DN	double negative, lymphocyte development stages expressing neither CD4 nor CD8 cell surface proteins, and including the thymic DN1, DN2, DN3 and DN4 stages of T-cell development
DNA	deoxyribonucleic acid
DNT cell	double negative T-cell) a CD3+ T-cell expressing neither CD4 nor CD8 cell surface markers
DP	double positive, lymphocyte development stages expressing both CD4 and CD8 cell surface proteins
DSH	domestic shorthair breed of cat
dUTP	deoxyuridine triphosphate
EBV	Epstein-Barr virus (alternatively termed human herpesvirus-4 (HHV-4))
EDTA	ethylenediaminetetraacetic acid
ELISA	enzyme-linked immunosorbent assay
F	inbreeding co-efficient, calculated as a percentage of the chances that two alleles in offspring will be identical by descent
FACS	fluorescence activated cell sorting
FADD	Fas-associated death domain protein
Fas	The Fas protein

<i>Fas</i>	the Fas gene (also termed CD95, Apo1, Apt and TNFRSF6 (tumour necrosis factor receptor superfamily member 6))
FasL	the Fas ligand protein
<i>FasL</i>	the Fas ligand gene
FeLV	feline leukaemia virus
FFPE	formalin-fixed paraffin-embedded
FITC	fluorescein isothiocyanate
FIV	feline immunodeficiency virus
FOCMA	feline oncornavirus cell membrane antigen
FSC	forward scatter
<i>Gld</i>	the generalised lymphoproliferative disease gene, one of the genes mutated in the mice with lymphoproliferative disease resembling autoimmune lymphoproliferative syndrome (ALPS) in people
H&E	haematoxylin and eosin
HEPES	4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid
HHV-4	human herpesvirus-4, alternatively termed Epstein Barr virus (EBV)
HHV-8	human herpesvirus-8, alternatively termed Kaposi 's sarcoma-associated virus
HIV	human immunodeficiency virus, the causative agent of acquired immunodeficiency syndrome (AIDS) in people
HNPCC	hereditary non-polyposis colorectal cancer
hpf	high power field
HRP	horseradish peroxidase
HSC	haematopoietic stem cell
HTLV-1	human T-cell leukaemia virus-1 type 1
<i>IGH</i>	immunoglobulin heavy chain locus, a gene present in B-cells that undergoes rearrangement early in B-cell development and used to assess B-cell clonality in lymphoid proliferations
IL	interleukin, one of a group of cytokines involved in a wide range of signalling processes
IFA	immunofluorescence antibody
LGL	large granular lymphocyte, a subset of lymphocytes characterised by intracytoplasmic azurophilic granules, and which in humans may be of natural killer (NK)-cell (CD3-) or mature T-cell (CD3+) lineage
LPD	lymphoproliferative disease (any disease, either neoplastic and non-neoplastic, in which abnormally excessive numbers of lymphocytes are produced)
<i>Lpr</i>	the lymphoproliferation gene, one of the genes that mutated in the mice with lymphoproliferative disease resembling autoimmune lymphoproliferative syndrome (ALPS) in people

lymphoma	a clonal proliferation of lymphocytes (lymphoid neoplasia)
lymphoblast	large lymphocyte
MAA	morphometric area analysis, used to calculate the apoptotic rate (AR) within tissue fields, determined by calculating the area of the relevant field(s) showing evidence of apoptosis (positive staining)
MALT	mucosa-associated lymphoid tissue, aggregations of lymphoid tissue at various mucosal sites throughout the body, particularly the gastrointestinal tract
MCC	morphometric cell count, used to calculate the apoptotic index (AI) within tissue fields, determined by counting the number of cells within the relevant field(s) showing evidence of apoptosis (morphology and positive staining)
MHC	major histocompatibility complex
MLH1	MutL homolog 1 protein, encoded by the <i>MLH1</i> gene
<i>MLH1</i>	the <i>MLH1</i> gene, one of the mismatch repair (MMR) genes, defects in which are associated with hereditary non-polyposis colorectal cancer (HNPCC) in people
MMR	mismatch repair, a highly conserved system within prokaryotes and eukaryotes that recognises and repairs errors in base insertion and deletion during DNA replication and recombination and repairs DNA damage
<i>MMR</i>	the mismatch repair genes, particularly including <i>MLH1</i> , <i>MSH2</i> and <i>MSH6</i>
mRNA	messenger ribonucleic acid
MSH2	MutS protein homolog 2 protein, encoded by the <i>MSH2</i> gene
<i>MSH2</i>	the <i>MSH2</i> gene, one of the mismatch repair (MMR) genes, defects in which are associated with hereditary non-polyposis colorectal cancer (HNPCC) in people
MSH6	mutS homolog 6 protein, encoded for by the <i>MSH6</i> gene
<i>MSH6</i>	the <i>MSH6</i> gene, one of the mismatch repair (MMR) genes, defects in which are associated with hereditary non-polyposis colorectal cancer (HNPCC) in people
NBS	Nijmegen breakage syndrome
NK cells	natural killer cells, a type of cytotoxic lymphocyte distinct from B-cells and T-cells, which in people usually express surface markers CD16 and CD56
NK T-cells	natural killer T-cells, a heterogeneous subset of T-cells with properties of both T-cells and natural killer (NK) cells
NMD	nonsense-mediated decay (of RNA)
<i>NRAS</i>	the neuroblastoma RAS gene
nRBCs	nucleated (immature) erythrocytes, typically metarubricytes
NZVP	New Zealand Veterinary Pathology

PALS	periarteriolar lymphoid sheath, a cuff of lymphocytes (mainly T-cells) surrounding small splenic arterioles and part of the splenic white pulp
PBMCs	peripheral blood mononuclear cells (includes lymphocytes and monocytes)
PBS	phosphate buffered saline
PCR	polymerase chain reaction
PCV	packed cell volume
PE	phycoerythrin
PEL	primary effusion lymphoma, an uncommon B-cell lymphoma typically presenting as an effusion without a tumour mass or nodal involvement, and most commonly associated with human herpes virus 8 (HHV-8) and human immunodeficiency virus (HIV) infection in people
PTGC	progressive transformation of germinal centres
Q1	British shorthair-Manx cross queen, dam of LPD-affected Litters 1 and 2
Q2	British shorthair queen, dam of LPD-affected Litter 0 and granddaughter of T1
qPCR	real-time polymerase chain reaction
REAL	Revised European/American Lymphoma classification
RIPA	radio-immunoprecipitation assay
RNA	ribonucleic acid
RT	room temperature
RT-PCR	reverse transcriptase polymerase chain reaction
SCID	severe combined immunodeficiency
SLE	systemic lupus erythematosus
SSC	side scatter
T1	British shorthair tom; sire of LPD-affected Litters 1 and 2, and both grand-sire and great-grand sire of LPD-affected Litter 0
T2	Oriental tom; sire of unaffected Litter 3
T3	Unknown tom; sire of Litter 4
T4	Unknown tom; sire of Litter 5
T5	British shorthair tom; sire of LPD-affected Litter 0 and son of T1
T6	British shorthair tom; common ancestor off all LPD-affected litters
TBS	tris-buffered saline
TCR	T-cell receptor
TCR $\alpha\beta$	a T-cell receptor composed of α and β protein chains
TCR $\gamma\delta$	a T-cell receptor composed of γ and δ protein chains

<i>TCRG</i>	the T-cell receptor γ locus, a gene present in T-cells that undergoes rearrangement early in T-cell development, and used to assess T-cell clonality in lymphoid cell proliferations
TdT	terminal deoxynucleotidyl transferase
TNF	tumour necrosis factor
TUNEL	terminal deoxynucleotidyl transferase dUTP nick end labelling, a method for used to detect the DNA fragmentation typically present when cells undergo apoptosis by labeling the terminal ends of nucleic acids
WAS	Wiskott-Aldrich Syndrome
WHO	World Health Organization
XLP	X-linked lymphoproliferative disease
χ^2	chi-square

